AP2280A - Compositions and methods for increasing telomeraseactivity. - Google Patents

Compositions and methods for increasing telomeraseactivity.

Info

Publication number
AP2280A
AP2280A AP2005003474A AP2005003474A AP2280A AP 2280 A AP2280 A AP 2280A AP 2005003474 A AP2005003474 A AP 2005003474A AP 2005003474 A AP2005003474 A AP 2005003474A AP 2280 A AP2280 A AP 2280A
Authority
AP
ARIPO
Prior art keywords
telomeraseactivity
compositions
increasing
methods
increasing telomeraseactivity
Prior art date
Application number
AP2005003474A
Other languages
English (en)
Other versions
AP2005003474A0 (en
Inventor
Calvin B Harley
Allison C Chin
Tsutomu Akama
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of AP2005003474A0 publication Critical patent/AP2005003474A0/xx
Application granted granted Critical
Publication of AP2280A publication Critical patent/AP2280A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
AP2005003474A 2003-06-23 2004-06-23 Compositions and methods for increasing telomeraseactivity. AP2280A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48098803P 2003-06-23 2003-06-23
PCT/US2004/020277 WO2005000245A2 (fr) 2003-06-23 2004-06-23 Compositions et methodes destinees a augmenter l'activite de la telomerase

Publications (2)

Publication Number Publication Date
AP2005003474A0 AP2005003474A0 (en) 2005-12-31
AP2280A true AP2280A (en) 2011-10-31

Family

ID=33551962

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003474A AP2280A (en) 2003-06-23 2004-06-23 Compositions and methods for increasing telomeraseactivity.

Country Status (24)

Country Link
US (3) US7846904B2 (fr)
EP (2) EP1644009B1 (fr)
JP (4) JP5583882B2 (fr)
KR (3) KR20110089887A (fr)
CN (1) CN1809364B (fr)
AP (1) AP2280A (fr)
AU (2) AU2004251753C1 (fr)
BR (1) BRPI0411856A (fr)
CA (1) CA2528483C (fr)
CY (2) CY1119951T1 (fr)
DK (2) DK1644009T3 (fr)
EA (1) EA009442B1 (fr)
ES (2) ES2666864T3 (fr)
HR (2) HRP20180330T1 (fr)
HU (2) HUE036559T2 (fr)
LT (2) LT1644009T (fr)
MX (1) MXPA05013844A (fr)
NZ (1) NZ544191A (fr)
PL (2) PL1644009T3 (fr)
PT (2) PT2548880T (fr)
SI (2) SI2548880T1 (fr)
TR (2) TR201903587T4 (fr)
WO (1) WO2005000245A2 (fr)
ZA (1) ZA200509846B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
DK1644009T3 (en) * 2003-06-23 2018-03-05 Telomerase Activation Sciences Inc Compositions for increasing telomerase activity and treating HIV infection
US9248088B2 (en) * 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning
WO2006113470A2 (fr) 2005-04-15 2006-10-26 Geron Corporation Procede pour traiter un cancer grace a l'inhibition combinee d'activites de proteasome et de telomerase
US8197860B2 (en) * 2005-06-23 2012-06-12 Nuliv Holding Inc. Method for enhancing nutrient absorption with astragalosides
CN100333731C (zh) * 2005-09-08 2007-08-29 南京医科大学 黄芪甲苷在制备治疗糖尿病周围神经病变药物中的应用
CN100384830C (zh) * 2006-01-12 2008-04-30 天津药物研究院 环黄芪醇类衍生物以及用途
US7992749B2 (en) 2006-03-30 2011-08-09 Nike, Inc. Support element for a carry strap
ES2696828T3 (es) 2006-10-30 2019-01-18 Geron Corp Inhibidor de telomerasa y gemcitabina combinados para el tratamiento del cáncer
CN101742906A (zh) 2007-06-04 2010-06-16 本古里安大学内盖夫研究发展局 三芳基化合物和包含它们的组合物
CN101225424B (zh) 2007-09-13 2013-05-29 天津药物研究院 环黄芪醇的单葡萄糖苷、其制备方法、药物组合物和应用
US8168596B2 (en) * 2008-10-17 2012-05-01 Nuliv Holding Inc. Use of cycloartane compounds for treating arthritis
US8481721B2 (en) * 2009-05-18 2013-07-09 Telomerase Activation Sciences, Inc. Compositions and methods for increasing telomerase activity
WO2014186603A1 (fr) * 2013-05-15 2014-11-20 Fybrands Corp. Compositions d'embellissement des cheveux, de la peau et des ongles
JP6657101B2 (ja) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ 糖尿病及びそれから生じる疾患合併症の治療のための化合物
CN104491185A (zh) * 2014-12-06 2015-04-08 郭亮 一种祛风湿药酒及其制备方法
CN104435371A (zh) * 2014-12-06 2015-03-25 郭亮 一种用于治疗关节炎的药酒
CN104435370A (zh) * 2014-12-06 2015-03-25 王香平 风湿保健酒
KR20160069857A (ko) 2014-12-09 2016-06-17 (주)스피어테크 텔로미어 활성을 증가시키기 위한 조성물 및 그 조성물의 제조방법
CN104817610A (zh) * 2015-03-15 2015-08-05 北京化工大学 利用硫酸水解制备环黄芪醇的方法
US10100285B2 (en) 2015-04-03 2018-10-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
SG11201707970XA (en) 2015-04-03 2017-10-30 Propagenix Inc Ex vivo proliferation of epithelial cells
CN106474094A (zh) * 2015-08-31 2017-03-08 南京理工大学 一种环黄芪醇电纺纤维膜及其制备方法
US10066201B2 (en) 2015-09-11 2018-09-04 Propagenix Inc. Ex vivo proliferation of epithelial cells
CN106307522A (zh) * 2016-11-06 2017-01-11 谭淞文 一种抗衰老保健品及其制备方法和食用方法
CN106831927B (zh) * 2017-02-07 2018-02-09 江西师范大学 一种黄芪甲苷的合成方法
CN108498521B (zh) * 2017-02-24 2020-05-05 北京大学 环黄芪醇在制备抑制腹主动脉瘤的药物中的应用
US10098922B1 (en) 2017-11-30 2018-10-16 Optigenex, Inc. Increasing telomere length in a cell
CA3145888A1 (fr) * 2018-07-31 2020-02-06 Isilay KAVADARLI Formulations ophtalmiques et leurs utilisations
CN111053782B (zh) 2018-10-17 2024-07-05 株式会社爱茉莉太平洋 包含人参皂苷的组合物
KR102635196B1 (ko) 2018-10-17 2024-02-13 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 미백 조성물
US11000538B2 (en) 2018-10-31 2021-05-11 Amorepacific Corporation Composition for enhancing exercise ability or anti-fatigue comprising novel ginsenoside
WO2020131058A1 (fr) * 2018-12-20 2020-06-25 Muhammed Majeed Potentiel d'amélioration de la télomérase d'ecdystérone
CN109942663B (zh) * 2019-04-22 2021-10-26 中国人民解放军联勤保障部队第九八九医院 利用双相酸水解制备环黄芪醇的方法
MX2019006749A (es) 2019-06-10 2022-11-28 Univ Mexico Nac Autonoma Compuestos activadores de senescencia celular.
KR20210037257A (ko) 2019-09-27 2021-04-06 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 피부 탄력 개선용 조성물
KR20210037256A (ko) 2019-09-27 2021-04-06 (주)아모레퍼시픽 신규 진세노사이드를 포함하는 갱년기 증상의 예방 또는 개선용 조성물
CN111419854B (zh) * 2020-05-18 2021-03-30 南通大学 具有特殊七元环结构的三萜在制备预防和治疗神经损伤药物中的应用
CN113480628B (zh) * 2021-08-17 2022-06-21 贵州师范大学 一种贵州疣螈多肽tk-cath及其编码基因和应用
CN113968894B (zh) * 2021-11-05 2024-05-28 山西大学 一种用黄芪甲苷降解制备环黄芪醇的方法
KR102666469B1 (ko) * 2023-05-04 2024-05-17 주식회사 아리바이오 텔로머라제 활성화제와 나노 입자를 포함하는 약물 전달용 조성물 및 이를 포함하는 탈모 예방, 개선 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770578A (en) * 1994-03-16 1998-06-23 Bergi Gmbh Use of triterpensaponins, such as notoginsenoside R1 (NR1) and/or astragaloside (ASIV) for preparing medicaments

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6212792A (ja) * 1986-07-18 1987-01-21 Osaka Chem Lab オウギサポニン類の単離法
JPS6212791A (ja) 1986-07-18 1987-01-21 Osaka Chem Lab オウギサポニン、その単離法およびその用途
IT1259645B (it) 1992-04-10 1996-03-25 Solis Srl Metodo per la rivelazione della variazione di densita' di un tessuto e dispositivo per la sua attuazione
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US6007989A (en) * 1992-05-13 1999-12-28 Board Of Regents, The University Of Texas System Methods of screening for compounds that derepress or increase telomerase activity
FR2695561B1 (fr) * 1992-09-17 1994-12-02 Lvmh Rech Gie Composition cosmétique ou dermatologique contenant au moins une saponine de type ginsenoside, et ses applications, notamment pour le soin des cheveux.
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
JPH07238026A (ja) * 1994-02-25 1995-09-12 Pola Chem Ind Inc 動脈硬化抑制剤及びこれを含む食品又は医薬
WO1996001835A1 (fr) * 1994-07-07 1996-01-25 Geron Corporation Telomerase mammifere
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US6162459A (en) * 1995-02-24 2000-12-19 National Science Council Acyclovir transdermal delivery system
AUPN411195A0 (en) * 1995-07-10 1995-08-03 Cathay Herbal Laboratories Pty Ltd Medicinal composition
CN1079265C (zh) 1995-08-01 2002-02-20 裴国增 灵芝口服液及其配制方法
US5785977A (en) * 1996-02-07 1998-07-28 Breithbarth; Richard Non-metallic microparticle carrier materials
US5916565A (en) * 1996-03-08 1999-06-29 In Clover, Inc. Product and method for treating joint disorders in vertebrates
TW452494B (en) * 1996-03-12 2001-09-01 Jang De Shan Herbal composition for stimulating blood circulation
US5900226A (en) * 1997-04-09 1999-05-04 Uop Llc Drying agents for non-foamed polyurethanes
JPH1036388A (ja) * 1996-07-25 1998-02-10 Kureha Chem Ind Co Ltd ジンセノサイド類含有ｈｓｐ４７合成抑制剤
SG94355A1 (en) 1996-10-01 2003-02-18 Geron Corp Human telomerase catalytic subunit
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
PT988044E (pt) * 1997-01-28 2008-04-07 Frank D Amelio Extracto de planta centipeda cunninghamii em água/etanol
US5786343A (en) * 1997-03-05 1998-07-28 Immudyne, Inc. Phagocytosis activator compositions and their use
ES2384552T3 (es) * 1997-09-05 2012-07-06 The Procter & Gamble Company Productos de limpieza y acondicionado para la piel o el pelo con mejor deposición de los ingredientes acondicionadores
DE69808790T3 (de) * 1997-09-12 2009-07-16 The Procter & Gamble Co., Cincinnati Hautreinigungs- und konditionierungsartikel für haut und haar
AU759437B2 (en) 1998-01-12 2003-04-17 Cold Spring Harbor Laboratory Extension of cellular lifespan, methods and reagents
GB9815177D0 (en) * 1998-07-13 1998-09-09 King S College London Treatment of skin disorders
AU5338199A (en) 1998-08-09 2000-02-28 Geron Corporation Methods and compositions for inhibiting or stimulating telomerase assembly
EP1133552A2 (fr) 1998-11-25 2001-09-19 Genetica, Inc. Methodes et reactifs d'augmentation de la capacite proliferative et de prevention de la senescence replicative
JP2000204091A (ja) * 1999-01-13 2000-07-25 Nippon Suisan Kaisha Ltd 新規ベンゾジオキソ―ル誘導体
JP2000229827A (ja) * 1999-02-05 2000-08-22 Kose Corp 皮膚外用剤
JP2000229834A (ja) * 1999-02-10 2000-08-22 Kanebo Ltd 化粧料
AUPQ127399A0 (en) 1999-06-29 1999-07-22 Guangzhou University Of Traditional Chinese Medicine Compositions and methods for treating or preventing osteoporosis
DK1210357T3 (da) 1999-09-10 2008-07-21 Geron Corp Oligonukleotid-N3' -P5' -thiophosphoramidater: syntese og anvendelse deraf
JP2001258505A (ja) * 2000-03-24 2001-09-25 Fancl Corp 食品組成物
CA2307393A1 (fr) * 2000-05-01 2001-11-01 The University Of British Columbia Chimiotherapie par administration d'un ginsenoside
US6277396B1 (en) * 2000-05-11 2001-08-21 Maximum Human Performance, Inc. Dietary supplement containing a thermogenic substance and an adrenal support substance
KR20030009454A (ko) 2000-05-31 2003-01-29 카가쿠키쥬쯔 신코지교단 진세노사이드Ｒｂ1으로 된 피부조직 재생촉진제
CN1172677C (zh) * 2000-07-14 2004-10-27 复旦大学附属中山医院 黄芪甲苷在制备药物组合物中的应用
GB0105613D0 (en) 2001-03-07 2001-04-25 Univ Cambridge Tech Pharmaceutically effective compounds and their use
WO2002007732A2 (fr) * 2000-07-26 2002-01-31 Cambridge University Technical Services Limited Composes efficaces sur le plan pharmaceutique et utilisation associee
US6696094B2 (en) * 2000-10-18 2004-02-24 Tzu-Sheng Wu Herbal pharmaceutical composition for treatment of HIV/AIDS patients
CN1242807C (zh) * 2000-11-08 2006-02-22 天津市延龄营养保健品有限公司 一种抗皮肤过敏的药物组合物及其制法和用途
CN1369276A (zh) * 2001-02-12 2002-09-18 徐秀荣 有效减轻体重的组合物和方法
JP2002275086A (ja) * 2001-03-15 2002-09-25 Fancl Corp 虚弱体質改善用組成物
WO2002091999A2 (fr) 2001-05-09 2002-11-21 Geron Corporation Traitement pour blessures
US20020182272A1 (en) * 2001-05-30 2002-12-05 Bruce Halstead Methods of treatment of HIV-associated conditions
US20040180938A1 (en) 2001-07-03 2004-09-16 Akio Ohtani Novel butadiene derivatives, process for preparation of the same and intermediates for the synthesis thereof
JP2003089687A (ja) * 2001-07-03 2003-03-28 Tanabe Seiyaku Co Ltd 新規ブタジエン誘導体、その製法およびその合成中間体
US6855344B2 (en) * 2001-07-17 2005-02-15 Integrated Chinese Medicine Holdings, Ltd. Compositions and methods for prostate and kidney health and disorders, an herbal preparation
US20030108629A1 (en) * 2001-07-17 2003-06-12 Chou Wen Hsien Compositions and methods for prostate and kidney health and disorders, an herbal preparation
CN1164608C (zh) * 2001-08-31 2004-09-01 上海中医药大学 具有抗心肌纤维化作用的黄芪皂甙甲
CN1406585A (zh) 2001-09-07 2003-04-02 中国科学院上海药物研究所 一种治疗病毒性心肌炎的药物组合物
JP2003160497A (ja) * 2001-11-22 2003-06-03 Toshin Kagaku Kk 皮膚外用剤
US20070042962A1 (en) * 2002-02-04 2007-02-22 Adams David S Peptide dependent upregulation of telomerase expression
CN1236803C (zh) 2002-03-20 2006-01-18 郑国芃 一种治疗风湿症的中药
CN1189176C (zh) * 2002-07-22 2005-02-16 江苏正大天晴药业股份有限公司 黄芪甲甙组合物及其制备方法
AU2003228378A1 (en) * 2003-03-26 2004-11-23 Westlake Partners Herbal compositions and methods for effecting weight loss in humans
AU2004249295A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating HIV
DK1644009T3 (en) 2003-06-23 2018-03-05 Telomerase Activation Sciences Inc Compositions for increasing telomerase activity and treating HIV infection
US9248088B2 (en) * 2003-06-25 2016-02-02 Telomerase Activation Sciences, Inc. Compositions and methods for skin conditioning
US20070122501A1 (en) * 2003-06-27 2007-05-31 Hong Kong University Of Science And Technology Formulations containing astragalus extracts and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770578A (en) * 1994-03-16 1998-06-23 Bergi Gmbh Use of triterpensaponins, such as notoginsenoside R1 (NR1) and/or astragaloside (ASIV) for preparing medicaments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABDALLAH R M ET AL: "ASTRAGALOSIDES FROM EGYPTIAN ASTRAGALUS SPINOSUS VAHL" DIE PHARMAZIE, GOVI VERLAG PHARMAZEUTISCHER VERLAG GMBH, ESCHBORN, DE, vol. 48, no. 6, 1 January 1993 (1993-01-01), pages 452-454 *
IONKOVA I ET AL: "Cycloartane saponin production in hairy root cultures of Astragalus mongholicus" PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 45, no. 8, 1 August 1997 (1997-08-01) , pages 1597-1600 *

Also Published As

Publication number Publication date
EP2548880A3 (fr) 2013-06-19
SI1644009T1 (en) 2018-04-30
DK1644009T3 (en) 2018-03-05
US8759304B2 (en) 2014-06-24
EA009442B1 (ru) 2007-12-28
MXPA05013844A (es) 2006-07-06
BRPI0411856A (pt) 2006-08-29
ES2716528T3 (es) 2019-06-13
HRP20180330T1 (hr) 2018-04-20
PT1644009T (pt) 2018-02-28
NZ544191A (en) 2008-12-24
CY1119951T1 (el) 2018-12-12
JP5583882B2 (ja) 2014-09-03
LT1644009T (lt) 2018-03-12
AP2005003474A0 (en) 2005-12-31
US20110071095A1 (en) 2011-03-24
KR101465515B1 (ko) 2014-11-26
US20150093455A1 (en) 2015-04-02
CA2528483C (fr) 2012-04-10
CY1121447T1 (el) 2020-05-29
PT2548880T (pt) 2019-02-27
KR101312389B1 (ko) 2013-09-27
ZA200509846B (en) 2007-04-25
SI2548880T1 (sl) 2019-04-30
JP2016041770A (ja) 2016-03-31
EP2548880A2 (fr) 2013-01-23
TR201903587T4 (tr) 2019-04-22
AU2004251753B2 (en) 2008-11-20
JP2007524627A (ja) 2007-08-30
HUE043168T2 (hu) 2019-08-28
EA200600076A1 (ru) 2006-08-25
WO2005000245A3 (fr) 2005-05-26
JP5913253B2 (ja) 2016-04-27
US20080113925A1 (en) 2008-05-15
KR20110089887A (ko) 2011-08-09
TR201802543T4 (tr) 2018-03-21
LT2548880T (lt) 2019-03-25
JP2011098991A (ja) 2011-05-19
AU2004251753C1 (en) 2009-04-09
US7846904B2 (en) 2010-12-07
AU2008249200A1 (en) 2008-12-18
CA2528483A1 (fr) 2005-01-06
JP2014024861A (ja) 2014-02-06
KR20060034237A (ko) 2006-04-21
PL2548880T3 (pl) 2019-07-31
CN1809364B (zh) 2010-06-16
EP2548880B1 (fr) 2019-01-09
EP1644009B1 (fr) 2017-11-29
PL1644009T3 (pl) 2018-07-31
HRP20190322T1 (hr) 2019-04-19
HUE036559T2 (hu) 2018-07-30
KR20130137252A (ko) 2013-12-16
JP5841337B2 (ja) 2016-01-13
AU2004251753A1 (en) 2005-01-06
EP1644009A4 (fr) 2010-04-07
CN1809364A (zh) 2006-07-26
EP1644009A2 (fr) 2006-04-12
WO2005000245A2 (fr) 2005-01-06
ES2666864T3 (es) 2018-05-08
DK2548880T3 (en) 2019-04-08

Similar Documents

Publication Publication Date Title
AP2280A (en) Compositions and methods for increasing telomeraseactivity.
AP2089A (en) Compositions and methods for combination antiviraltherapy
HK1209729A1 (en) Compounds, compositions and methods
EP1646382A4 (fr) Composes, compositions et procedes
EP1692112A4 (fr) Composes, compositions, et methodes associees
AU2003262747A8 (en) Compounds, compositions, and methods
EP1503993A4 (fr) Composes, compositions et procedes
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
EP1664746A4 (fr) Capteur d'antioxydants, procedes et compositions associes
HK1070656A1 (en) Compounds, compositions, and methods
GB0411940D0 (en) Methods and compositions
IL175300A0 (en) Indirubin-type compounds, compositions, and methods for their use
AU2003270015A8 (en) Compounds, compositions, and methods
EP1701725A4 (fr) Methodes et compositions
AU2003299612A8 (en) Compounds, compositions and methods
PL1651042T3 (pl) Kompozycja chwastobójcza o zwiększonym działaniu chwastobójczym i sposób zwiększania działania chwastobójczego
IL167936A0 (en) Compounds, compositions,and methods
EP1711527A4 (fr) Anticorps specifiques de hla-dr, compositions et methodes associees
AU2003290507A8 (en) Compounds, compositions and methods
EP1675834A4 (fr) Composes, compositions et methodes
AU2003277079A8 (en) Compounds, compositions, and methods
EP1594849A4 (fr) Composes, compositions, et methodes
EP1680420A4 (fr) Composes, compositions et methodes
EP1620092A4 (fr) Composes, compositions et methodes